Pulmonary surfactant therapy.
Surfactant replacement therapy is now an integral part of the care of neonates since several clinical trials of natural surfactant extracts and synthetic preparations have shown efficacy in the treatment of infants with hyaline membrane disease. In these studies, early treatment with exogenous surfactant substantially reduced mortality and the incidence of air leak, although it did not appear to reduce the incidence of other complications, in particular bronchopulmonary dysplasia. Early reports of exogenous surfactant therapy in patients with the adult respiratory distress syndrome, although promising, remain limited in number. More research is needed to improve on current modes of therapy and to investigate the possible role of surfactant in other lung diseases of both newborns and adults.
Poulain
F R
FR
Department of Pediatrics, University of California, San Francisco, School of Medicine.
Clements
J A
JA
D000328:Adult; D002986:Clinical Trials as Topic; D006801:Humans; D007231:Infant, Newborn; D008171:Lung Diseases / Q000628:therapy; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000503:physiopathology / Q000628:therapy; D015656:Respiratory Mechanics
D011663:Pulmonary Surfactants